UK: Medical Cannabinoids Jazz Pharmaceuticals to Take Over GW Pharmaceuticals for 7.2 Billion Dollars

Editor: Ahlam Rais

The global pharma company Jazz Pharmaceuticals has plans to acquire GW Pharmaceuticals, one of the leaders in developing cannabinoid-based medicines. The move is expected to attract many more investments into this sector.

Related Companies

The cannabis sector is still in the early phase of its growth to becoming a more mainstream Consumer and Healthcare category.
The cannabis sector is still in the early phase of its growth to becoming a more mainstream Consumer and Healthcare category.
(Source: Pixabay)

UK – The Medical Cannabis and Wellness Ucits ETF is Europe’s first ETF focused on cannabis. The fund trades in London under CBDX and in Germany as CBSX and is passported for sale across Europe. It has focused on the medical side of Cannabis with pharmaceutical companies such as GW Pharma at the core of its portfolio – it accounts for around 14 % of the fund’s holdings.

Nawan Butt, Portfolio Manager of The Medical Cannabis and Wellness Ucits ETF, said: “GW Pharmaceuticals is a UK based company that made history by getting the first FDA approved drug derived from Cannabis. Their drug, Epidiolex has changed the lives of many living with epilepsy, and they are building out a platform looking at other areas. When they started most global pharma companies were hesitant to do work with this plant ignoring centuries of evidence that there were some health benefits. As times are changing and attitudes adjusting, more and more companies are getting involved with the sector. The traditional pharma company, Jazz pharma, has agreed to purchase GW Pharma for over 7 billion dollars. We don’t think this is the last deal we will see in the sector.”

China’s Pharmaceutical Equipment Market - Current Status, Trends and Recommendations for Action

As China is emerging as one of the world’s fastest-growing markets for the consumption of pharmaceuticals, it also offers huge opportunities for the global equipment industry.

This 40-page report aims to help you gain a better understanding of the current China's pharmaceutical market regarding a series of pharmaceutical industry related policies. Based on results of the survey among users in the pharmaceutical industry and the expert interviews, it will also provide you with a forecast for the industry and recommendations for your future operating and investment in China.

Butt continues, “One of the sectors that benefited the most from the US results was Cannabis. The sector is still in the early phase of its growth to becoming a more mainstream Consumer and Healthcare category and with the Democrats in power we expect the move towards legalization in the US to speed up. With this reality becoming more widely appreciated we have seen many of the US recreational focused cannabis names do extremely well over the past month. But now the focus of the sector could switch to the medical side. Today’s events should draw attention to other companies doing work in this sector and the opportunities they are exploring.”

(ID:47114034)